NCT03866382 2026-03-18
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
Phase 2 Recruiting
National Cancer Institute (NCI)
Mayo Clinic
The Netherlands Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
Fudan University
Sun Yat-sen University
Fudan University